The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk
about
Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy.
P2860
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk
@ast
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk
@en
type
label
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk
@ast
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk
@en
prefLabel
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk
@ast
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk
@en
P2860
P356
P1476
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk
@en
P2093
David M Kent
P2860
P304
P356
10.7326/M14-2767
P407
P577
2015-06-01T00:00:00Z